GGrantIndex
← Search

Recombinant Virus Vaccines

$1,717,946ZIAFY2023AINIH

National Institute Of Allergy And Infectious Diseases

Investigators

Linked publications & trials

Abstract

During F7'23 progress has been made in developing an improved vaccine for mpox and infections caused by other orthopoxviruses. One approach carried in collaboration with the company Moderna uses mRNAs expressing four modified mpox virus proteins encapsulated in a lipid particle. We have shown that the single mRNAs are immunogenic and provide partial protection and multiple mRNAs provide complete protection against vaccinia virus in mouse models. In a second approach we have made protein nanoparticles containing multiple copies of truncated mpox virus proteins and showed that they also completely protect against vaccinia virus infection in a mouse model.

View original record on NIH RePORTER →